Skip to main content

Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?

Publication ,  Journal Article
Farnier, M
Published in: Annals of Translational Medicine
February 2018

Duke Scholars

Published In

Annals of Translational Medicine

DOI

EISSN

2305-5847

ISSN

2305-5839

Publication Date

February 2018

Volume

6

Issue

3

Start / End Page

60 / 60

Publisher

AME Publishing Company

Related Subject Headings

  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Farnier, M. (2018). Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe? Annals of Translational Medicine, 6(3), 60–60. https://doi.org/10.21037/atm.2018.01.02
Farnier, Michel. “Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?Annals of Translational Medicine 6, no. 3 (February 2018): 60–60. https://doi.org/10.21037/atm.2018.01.02.
Farnier, Michel. “Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?Annals of Translational Medicine, vol. 6, no. 3, AME Publishing Company, Feb. 2018, pp. 60–60. Crossref, doi:10.21037/atm.2018.01.02.
Farnier M. Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe? Annals of Translational Medicine. AME Publishing Company; 2018 Feb;6(3):60–60.

Published In

Annals of Translational Medicine

DOI

EISSN

2305-5847

ISSN

2305-5839

Publication Date

February 2018

Volume

6

Issue

3

Start / End Page

60 / 60

Publisher

AME Publishing Company

Related Subject Headings

  • 42 Health sciences
  • 32 Biomedical and clinical sciences